Allos Therapeutics names new board member

Mr Stout served most recently as president of pharmaceuticals at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior to that, he served as president of US pharmaceuticals at GlaxoSmithKline from 1999 to January 2003.

Paul Berns, president and CEO of Allos, said: “David’s 30-plus years of experience in the pharmaceutical industry will be valuable as we approach the potential commercialization of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma and continue to drive our product development and commercialization plan for pralatrexate in both hematologic malignancies and solid tumors.”